NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis $25.01 -3.23 (-11.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$23.73▼$28.8250-Day Range$25.01▼$38.7352-Week Range$12.57▼$42.50Volume1.94 million shsAverage Volume701,756 shsMarket Capitalization$944.93 millionP/E RatioN/ADividend YieldN/APrice Target$50.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tarsus Pharmaceuticals alerts: Email Address Tarsus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside103.3% Upside$50.83 Price TargetShort InterestBearish23.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.73) to ($2.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.40 out of 5 starsMedical Sector741st out of 936 stocksBiological Products, Except Diagnostic Industry125th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTarsus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.32% of the outstanding shares of Tarsus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 4.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARS. Previous Next 2.7 News and Social Media Coverage News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Tarsus Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.25% of the stock of Tarsus Pharmaceuticals is held by insiders.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($3.73) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tarsus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Read More TARS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TARS Stock News HeadlinesJuly 27 at 12:59 AM | finance.yahoo.comQuestex’s Fierce Pharma Announces the 2024 Fierce Pharma Marketing Awards FinalistsMay 29, 2024 | globenewswire.comTarsus to Participate in Upcoming Investor ConferencesJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 28, 2024 | seekingalpha.comFollowing Up On Tarsus PharmaceuticalsMay 22, 2024 | investing.comTarsus Pharmaceuticals Inc (TARS)May 12, 2024 | finance.yahoo.comEarnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their EstimatesMay 10, 2024 | finance.yahoo.comTarsus Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | markets.businessinsider.comAnalyst Ratings For Tarsus PharmaceuticalsJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 9, 2024 | globenewswire.comTarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare ConferenceMay 9, 2024 | finanznachrichten.deTarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsMay 9, 2024 | msn.comTarsus Pharmaceuticals GAAP EPS of -$1.01 beats by $0.18, revenue of $27.61M beats by $9.71MMay 9, 2024 | finance.yahoo.comTarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | investorplace.comTARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comTarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsMay 7, 2024 | markets.businessinsider.comTarsus Pharmaceuticals earnings: here's what Wall Street expectsMay 1, 2024 | globenewswire.comTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024May 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Organon (OGN) and Exelixis (EXEL)See More Headlines Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TARS CUSIPN/A CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$50.83 High Stock Price Target$61.00 Low Stock Price Target$30.00 Potential Upside/Downside+103.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,890,000.00 Net MarginsN/A Pretax Margin-348.22% Return on Equity-71.12% Return on Assets-55.30% Debt Debt-to-Equity Ratio0.11 Current Ratio8.01 Quick Ratio7.92 Sales & Book Value Annual Sales$42.56 million Price / Sales22.20 Cash FlowN/A Price / Cash FlowN/A Book Value$5.95 per share Price / Book4.20Miscellaneous Outstanding Shares37,782,000Free Float34,665,000Market Cap$944.93 million OptionableOptionable Beta1.05 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Bobak R. Azamian M.D.Co-Founder, President, CEO & ChairmanMr. Jeffrey S. Farrow (Age 62)CFO & Chief Strategy Officer Comp: $722.95kDr. Seshadri Neervannan Ph.D. (Age 56)Chief Operating Officer Comp: $759.2kDr. Elizabeth Yeu Lin M.D. (Age 46)Chief Medical Advisor & Director Comp: $59.12kMr. David NakasoneHead of Investor RelationsDr. Bryan Wahl J.D. (Age 46)M.D., General Counsel & Corporate Secretary Comp: $619.09kMs. Adrienne KempSenior Director of Corporate CommunicationsMr. Matthew Rossen M.B.A. (Age 46)Vice President of Marketing Mr. Scott YoumansVice President of SalesMs. Dianne C. Whitfield M.S.W. (Age 47)Chief Human Resources Officer Comp: $578.9kMore ExecutivesKey CompetitorsPrevail TherapeuticsNASDAQ:PRVLHarpoon TherapeuticsNASDAQ:HARPCellular Biomedicine GroupNASDAQ:CBMGCabaletta BioNASDAQ:CABAMeiraGTxNASDAQ:MGTXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 11,237 shares on 7/26/2024Ownership: 0.479%Bank of New York Mellon CorpBought 26,225 shares on 7/26/2024Ownership: 0.325%Calamos Advisors LLCSold 2,474 shares on 7/25/2024Ownership: 0.020%Assenagon Asset Management S.A.Bought 1,063,422 shares on 7/18/2024Ownership: 2.815%SG Americas Securities LLCSold 6,811 shares on 7/12/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions TARS Stock Analysis - Frequently Asked Questions How have TARS shares performed this year? Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of the year. Since then, TARS shares have increased by 23.5% and is now trading at $25.01. View the best growth stocks for 2024 here. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its earnings results on Wednesday, May, 8th. The company reported ($1.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.14. The company had revenue of $27.61 million for the quarter, compared to analysts' expectations of $17.94 million. When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (2.81%), Allspring Global Investments Holdings LLC (0.48%), Bank of New York Mellon Corp (0.32%) and Calamos Advisors LLC (0.02%). Insiders that own company stock include Vivo Capital Ix, Llc, Michael Ackermann, Seshadri Neervannan, Aziz Mottiwala, Bryan Wahl, Leonard M Greenstein, Dianne C Whitfield, Bobak R Azamian, Elizabeth Yeu Lin, Mark J Holdbrook, Andrew D Goldberg and Jose M Trevejo. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TARS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts